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ABSTRACT 
 
The thioredoxin system, composed of thioredoxin and thioredoxin reductase, 
emerges as one of the most important thiol-based systems involved in the 
maintenance of the cellular redox balance. Thioredoxin-like-1 (TXL-1) is a highly 
conserved protein comprising an N-terminal thioredoxin domain and a C-terminal 
domain of unknown function. Here we show that TXL-1 is a substrate for the 
cytosolic selenoprotein thioredoxin reductase. In situ hybridization experiments 
demonstrates high expression of Txl-1 mRNA in various areas of central nervous 
system and also in some reproductive organs. Glucose deprivation, but not 
hydrogen peroxide treatment, reduced the levels of endogenous TXL-1 protein in 
HEK-293 cell line. Conversely, overexpression of TXL-1 protects against glucose 
deprivation-induced cytotoxicity. Taken together, the finding that Txl-1 mRNA is 
highly expressed in tissues which use glucose as a primary energy source and the 
modulation of TXL-1 levels upon glucose deprivation indicate that TXL-1 might be 
involved in the cellular response to sugar starvation stress. 
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INTRODUCTION 
 
The thioredoxin family encompasses a group of redox proteins that function as 
general protein disulphide reductases [8] participating in many physiological and 
pathophysiological processes [1,5]. The redox activity of thioredoxins (Trx) is directly 
linked to their highly conserved active site (Cys-Gly-Pro-Cys) where the cysteine 
residues can undergo a reversible oxidation from a dithiol to a disulphide form. 
Oxidized inactive forms are reduced by the selenoprotein thioredoxin reductase 
(TrxR), which uses the reducing power of NADPH [9]. Thioredoxins share a common 
globular structure consisting of a central core of β-sheets surrounded by α-helixes 
with the active site situated in a protrusion of the protein surface [12]. 
 Different forms of thioredoxins have been reported in all organisms from 
prokaryotes to humans. In eukaryotic organisms thioredoxins are located in different 
subcellular compartments and are found either ubiquitously expressed or specifically 
localized in particular tissues [2,8,11,17,20,21,23]. Some of the previously described 
thioredoxins comprise additional domains with known or unknown counterparts in 
the databases [2,17,21,22,26,27].  
Thioredoxin-like 1 (TXL-1), also known as TRP32 [17,21] is a two-domain protein 
of 32 kDa composed of a N-terminal thioredoxin domain followed by a C-terminal 
domain of unknown function with no homology with any other protein in the 
databases. TXL-1 mRNA is ubiquitously localized in all human tissues examined so 
far, although it is present at highest levels in tissues with an elevated metabolic rate 
[17,21]. The crystal structure of the TXL-1 N-terminal domain has been solved [14] 
and shows a monomeric structure, in contrast to the ubiquitous cytosolic TRX-1 
which is dimeric in all crystal structures reported [37]. 
We report here novel features of human TXL-1 concerning its ability to serve as 
substrate for thioredoxin reductase, new insights into its tissue localization and, more 
importantly, that TXL-1 is involved in the cellular response to glucose deprivation.  
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MATERIAL AND METHODS 
 
Materials: All media and supplements used for cell culture including glucose-free 
DMEM were purchased from Life Technologies. Bovine thioredoxin reductase was 
from IMCO (Sweden). pET-15b vector was obtained from Novagen and pGEX-4T-1 
vector was from Amersham Biosciences. pCDNA-myc empty vector was a gift from 
Dr. Eckardt Treuter. Anti-myc monoclonal antibody was purchased from Invitrogen. 
H2O2, Trypan Blue and MTT reagents were obtained from Sigma-Aldrich.  
 
Human TXL-1 protein expression and purification: The ORF encoding human 
TXL-1 was cloned into the BamHI-EcoRI sites of the pGEX-4T-1 expression vector 
and used to transform E. coli HMS174(DE3). Induction and purification of the 
recombinant protein was achieved as previously reported [21]. Thrombin (5 units/mg 
of fusion protein) was used to remove the glutathione S-transferase domain by 
incubation overnight at 4°C. The resulting protein preparation was then subjected to 
ion exchange chromatography using a Resource Q column (Amersham 
Biosciences), and human TXL-1 was eluted as a single peak using a gradient of 
NaCl. Protein concentration was determined with the Bio-Rad protein assay kit (Bio-
Rad) using BSA as a standard. 
 
Enzymatic Activity Assays: Enzymatic activity of recombinant human TXL-1 was 
performed using two different assays. In the DTT assay, DTT is used as reducing 
agent and the assay was carried out as previously described [38]. In the thioredoxin 
reductase assay, recombinant TXL-1 activity was determined by its capability to 
reduce insulin disulfide bonds using NADPH as electron donor in the presence of 
calf thymus thioredoxin reductase-1. The activity assay was performed essentially as 
described elsewhere [33] but monitoring insulin precipitation at 600nm. In both 
cases, human TRX-1 was used as control. 
 
Antibody production: Purified His-hTXL-1 [21] was used to immunize rabbits 
(Zeneca Research Biochemicals). After six immunizations, serum from rabbits was 
purified by ammonium sulfate precipitation. Affinity-purified antibodies were prepared 
as described [24] using the TXL-1 fragment from the GST-TXL-1 recombinant 
protein. The specificity of the antibodies was tested by western blot. 
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Immunodetection was performed with horseradish peroxidase-conjugated donkey 
anti-rabbit IgG diluted 1/5,000 following the ECL protocol (Amersham Biosciences). 
Additionally, affinity purified polyclonal rabbit anti-TXL-1 and the respective blocking 
peptide were purchased from Abgent (San Diego, USA) for immunocytochemistry. 
 
In situ hybridization: Adult (NMRI, weighting 20-25 g) and embryonic (embryonic 
days E9 – E18; E1 = the day of copulation plug) mice were used. Adult animals were 
killed with carbon dioxide, the tissues and embryos were rapidly excised, and frozen 
on dry ice. The frozen tissues were sectioned with Microm HM-500 cryostat at 14 µm 
and mounted on Polylysine glass slides (Menzel, Braunschweig, Germany). The 
sections were stored at –20ºC until use. Three oligonucleotide probes directed 
against mouse and rat Txl-1 mRNA (mouse nucleotides 189-222, 263-294 and 361-
394, GeneBank accession number NM_016792) were used for in situ hybridization. 
The sequences exhibited less than 60% homology with other known genes in the 
GeneBank database. Several probes against non-related mRNAs with known 
expression patterns and with similar length and GC-content were used as controls. 
Addition of 100-fold excess of non-labeled probes quenched all signal. The in situ 
hybridization was carried out as described in detail previously [28]. 
 
Immunocytochemistry: For immunocytochemistry adult NMRI mice were perfused 
first with 20ml of physiological saline followed with 50ml of 4% paraformaldehyde in 
phosphate buffered saline (PBS, 0.1M, pH 7.3). The brains were excised and further 
immersed in the same fixative for 1 h. After cryoprotection with 20% sucrose the 
tissues were sectioned at 10µm in Microm 500HM cryostat. Sections were incubated 
with the antibody (dil. 1:100) overnight in PBS containing 1% BSA and 0.1% Triton 
X-100. Immunoreactivity was visualised with Vectastain Elite-kit (Vector 
Laboratories, Burlingame, Ca, USA) using nickel-intensified diaminobenzidine as a 
chromogen. Presaturation of the antibody with 40µg of the blocking peptide and 
omission of the primary or secondary antibodies abolished all staining. Sections 
were examined under a Nikon FXA microscope equipped with a PCO Sensicam 
digital camera (PCO, Kelheim, Germany) and the images were processed using 
Corel Draw software (Corel Corporation Ltd., Ontario, Canada). 
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Cell culture and transient transfections: HEK-293 cells were cultured at 37ºC in 
an atmosphere of 5% CO2 in DMEM medium supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Transfection experiments 
were carried out as described elsewhere [13]. 
 
Stable transfection of HEK-293 cells: Plasmids pCDNA-myc and pCDNA-
myc/TXL-1 were transfected into HEK-293 cells. Selection for G418 resistance (1 
mg/ml) was initiated 48h after transfection and individual clones were isolated to 
obtain three different stable cell lines: control clone transfected with empty pCDNA-
myc vector and two clones transfected with pCDNA-myc/TXL-1 showing different 
TXL-1 expression levels. TXL-1 overexpression was confirmed by western-blot 
analysis using anti-myc (not shown) and anti-TXL-1 antibodies. 
 
MTT cell viability assay: Cell viability was assessed by MTT assay [25] that detects 
the cellular ability to transform MTT tetrazolium salt into formazan. MTT (0.3 mg/ml 
in DMEM without phenol red) was added to the cells. After 1 h incubation at 37ºC, 
the medium was removed and the formazan crystals were dissolved in the same 
volume of isopropanol. Aliquots were transferred to 96-well plates and the 
absorbance was measured at 540nm. Results were expressed as a percentage of 
viable cells. 
 
Statistical analysis: Analyses of differences were carried out by ANOVA followed 
by the Student-Newman-Keuls post-hoc test. A value of p<0.05 was considered 
statistically significant. 
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RESULTS 
 
Txl-1 is a two-domain protein conserved from fission yeast to humans  
 
A protein-protein BLASTp search was performed to identify human TXL-1 
orthologues in the public databases (http://www.ncbi.nlm.nih.gov/BLAST/), which 
resulted in several entries from the fission yeast to mammals. All these sequences 
were run on a W-Clustal alignment using the MegAlign program included in the 
DNAstar software package (Supplemental Data Fig. 1). Txl-1 protein is well 
conserved from lower eukaryotes to humans and the high identity is not only 
confined to the thioredoxin domain, but being comparable all along the protein 
sequence. All the Txl-1 proteins analyzed are about the same length (290 residues) 
and contain many of the amino acid residues identified as essential for catalysis, 
maintenance of three-dimensional structure or protein-protein interactions in 
previously characterized thioredoxins [3]. 
As mentioned above, Txl-1 is a two-domain protein with an N-terminal thioredoxin 
domain and a C-terminal domain with unknown function [17,21]. Nonetheless, the 
examination of the Conserved Domain Database at NCBI 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) showed that two other classes 
of proteins different than Txl-1 contain a homologous domain, which is named 
Domain of Unknown Function 1000 (DUF1000). These two classes of proteins are 
the eukaryotic HT014 proteins, which comprise a unique DUF1000 domain, and the 
Caenorhabditis elegans ZK353.1 protein that encompasses a Cyclin N-terminal 
domain (Cyclin box fold) and a C-terminal DUF1000 domain. 
 
Human TXL-1 has reducing activity coupled to thioredoxin reductase 
 
We have now purified a GST-TXL-1 recombinant protein and assayed the 
thrombin-cleaved TXL-1 in the DTT assay resulting in detectable enzymatic activity, 
as previously reported [17] (data not shown). Recombinant thrombin-cleaved TXL-1 
protein also displayed thioredoxin reducing activity in the presence of calf thymus 
thioredoxin reductase and NADPH (Fig. 1). Remarkably, the kinetics of TRX-1 and 
TXL-1 are different. First, TRX-1 shows a 4-fold higher thioredoxin activity than TXL-
1 at the same concentration. Second, TXL-1 activity is delayed in time when 
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compared to that of TRX-1. TXL-1 starts to show the enzymatic activity after 45 min 
of initiating the assay, when TRX-1 has already reached its maximal activity. This 
long latency phase explains the failure to detect thioredoxin reductase-dependent 
activity of TXL-1 in our previous report [21].  
 
Txl-1 mRNA tissue distribution 
 
With in situ hybridization in mice, high level of Txl-1 mRNA could be seen in 
several areas in nervous system. Especially olfactory bulb, hippocampus, habenular 
nucleus, several hypothalamic (Fig. 2A) and brain stem nuclei and cerebellar cortex 
(Fig. 2B) showed high expression. In peripheral nervous system moderate 
expression was seen in the neurons of trigeminal and superior cervical ganglion (Fig. 
2C). In reproductive organs high expression was seen in the granulosa cells of 
different size follicles in ovary, while interstitial tissue and corpora lutea showed low 
expression (Fig. 2D). In testis moderate signal was observed in most seminiferous 
tubules (Fig. 2E). In epididymis strong signal was present in the epithelium of the 
tubules (Fig. 2F). In prostate low signal was seen in the epithelium (Fig. 2G) and in 
seminal vesicle low expression was seen in the muscle layer. In immune system 
moderate levels of Txl-1 mRNA were observed in thymus (Fig. 2H), spleen and 
lymph nodes. In kidney moderate expression was present in the cortex and outer 
medulla while inner medulla and pelvis were devoid of signal (Fig. 2I). In urinary 
bladder low signal was present in the epithelium whereas muscle layer was devoid 
of signal. In salivary gland and liver (Fig. 2J) moderate homogenous signal was 
present. Pituitary gland and adrenal gland (Fig. 2K) showed low signal while thyroid 
gland was devoid of signal. In heart (Fig. 2L) and striated muscle (Fig. 2M) 
expression of Txl-1 mRNA was low. In skin low expression could be detected (Fig. 
2M). Strong Txl-1 mRNA expression was seen in the embryonic side of the E9 
placenta, while maternal side showed low expression. In E9 fetus clear signal was 
seen in the neuroepithelium of developing neural tube (Fig. 2N). Most organs which 
express Txl-1 mRNA in adults showed expression already during fetal development 
(data not shown). 
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Immunocytochemical localization of TXL-1 in brain 
 
As the central nervous system is one of the organs showing high levels of Txl-1 
mRNA, we further analyzed the expression pattern of Txl-1 protein in mouse brain 
tissue by immunocytochemistry. 
Txl-1 immunoreactivity could be seen in several brain areas. Strong staining was 
seen in e.g. cerebral and cerebellar cortex (Fig. 3A) and hypothalamus (Fig. 3B). In 
cerebellar Purkinje neurons strong nuclear staining was evident. Moderate to low 
labeling was seen in the cytoplasm (Fig. 3A). Large number of granular neurons 
showed strong nuclear labeling and weak cytoplasmic staining. Few granular 
neurons exhibited moderate cytoplasmic staining with weak or non-labeled nucleus 
(Fig. 3A). In hypothalamic arcuate nucleus both nuclear and cytoplasmic staining 
was seen in most of the labeled cells while in some on cytoplasmic staining was 
evident (Fig. 3B). No staining was seen in the presaturation control (Fig. 3C).  
In addition, we clearly observed both nuclear and cytoplasmic localization of a 
TXL-1-GFP fusion protein (Supplemental Data Fig. 2). Although the nuclear staining 
is weaker than with a transfection control using the pEGFP-N3 empty vector 
expressing the GFP protein alone, a comparison with cells transfected with pEGFP-
N3/SPTRX-2 that express the cytoplasmic-restricted sperm-specific thioredoxin 2 
[26] allow us to unequivocally confirm the nuclear labeling of TXL-1-GFP fusion 
protein. 
 
Glucose deprivation but not hydrogen peroxide affects TXL-1 expression 
levels in HEK-293 cells 
 
Brain tissue is very sensitive to ischemia (i. e. hypoxia and glucose deprivation). In 
addition, glucose deprivation induces cell death through a mechanism where 
metabolic oxidative stress is involved [18,30,31]. We wanted to know whether TXL-1 
might be involved in this mechanism and therefore we investigated TXL-1 
expression in HEK-293 cells after glucose deprivation. First, we confirmed that 
glucose-deprivation, as reported for other cell lines [18,32], induces cell death in 
HEK-293 cells (Fig. 4, left panel). Cytotoxicity is evident after 24h of treatment, 
counting up to 60% of cell death after 48h. With regard to TXL-1 expression upon 
glucose deprivation, TXL-1 protein levels do not change until 32 h (not shown) and 
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decrease after 36 h when HEK-293 cells are cultured in glucose-free medium (Fig. 4, 
right panel). In contrast, glucose deprivation does not affect TRX-1 or actin protein 
levels up to 48h.  
Glucose deprivation-induced cytotoxicity is mediated by the generation of reactive 
oxygen species such as hydrogen peroxide [30]. Based on our previous results, we 
reasoned that the downregulation of TXL-1 expression caused by glucose 
deprivation might be mediated by hydrogen peroxide. Therefore, we checked 
whether hydrogen peroxide by itself might trigger modifications on TXL-1 protein 
levels. As shown in Fig. 5, hydrogen peroxide induces HEK-293 cell death within 2 h, 
reaching only 50% survival after 6 h, but does not cause any change in the 
endogenous levels of TXL-1. Extended incubation times caused massive cell death 
without any change in the levels of TXL-1 (not shown). 
 
TXL-1 overexpression protects against glucose deprivation induced 
cytotoxicity 
 
Next we wanted to know if TXL-1 overexpression might abolish or delay the cell 
death induced by glucose deprivation in HEK-293 cells. For this purpose, we made 
stable cell lines overexpressing TXL-1 to check whether constitutively increased 
TXL-1 protein levels have a protective effect on glucose deprivation-induced 
cytotoxicity. As shown in Fig. 6 we managed to isolate two stable clones with 
different TXL-1 expression levels (TXL-1-6 and TXL-1-16, with high and low 
expression levels of recombinant TXL-1, respectively) and one stable cell line with 
the pCDNA-myc empty vector to be used as negative control. Our results indicate 
that increased levels of TXL-1 can protect against the cytotoxicity induced by 48 to 
72 h of glucose deprivation (Fig. 6). Thus, TXL-1-6 clone that expresses high levels 
of TXL-1 protein shows a significant delay in cell death and a higher rate of survival 
(about 50% more living cells than the control) from 48 h to 72 h (Fig. 6). However, 
TXL-1-16 clone that expresses low levels of TXL-1 is as sensitive as the control. In 
contrast, TXL-1 overexpression does not exert any effect against hydrogen peroxide 
cytotoxicity (not shown). 
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Discussion 
 
Oxidative stress is involved in the progression of many different diseases and it is 
characterized by the depletion of the general antioxidant systems leading to an 
alteration of the cellular redox status. Thus, the balance between ROS production 
and antioxidants determines the degree of oxidative stress [4]. Thioredoxins have 
emerged as an essential family of proteins directly related to the antioxidant cellular 
network [5]. Here we present novel features of one member of the thioredoxin family, 
thioredoxin-like-1. 
Txl-1 is one of the best conserved members of the thioredoxin family. This fact 
probably implies an important function of this protein in the physiology of eukaryotic 
organisms. It is also remarkable that the active site of Txl-1 homologues in lower 
eukaryotes and invertebrates contains a tryptophan residue (WCGPC), as is also the 
case of most thioredoxins [10], while in Txl-1 from vertebrates, this tryptophan 
residue is substituted by a glycine residue (GCGPC). The presence of the bulky 
imidazole side chain of Trp31 has been proposed to regulate the catalytic activity of 
thioredoxins [16]. Indeed, we found that the thioredoxin activity kinetics are 
considerably different between TXL-1 and TRX-1, making it reasonable to speculate 
that the substitution of Trp31 to Gly31 might explain this difference. Nonetheless, the 
biological significance of this change requires further analysis. 
High expression of Txl-1 mRNA could be seen in tissues which mainly use glucose 
as an energy source and low expression in tissues which utilize fatty acids as energy 
supplier. This finding aimed us to further investigate the localization of Txl-1 in brain, 
which in normal situation relies solely on glucose. Our results show that Txl-1 can be 
seen either in the nucleus or the cytoplasm of different cells types in the brain (Fig. 
3). In addition, a TXL-1-GFP fusion protein also displays both nuclear and 
cytoplasmic localization (Supplementary Data Fig. 2), thus confirming the TXL-1 
subcellular localization pattern observed with immunocytochemistry. However, there 
is no nuclear targeting signal in the TXL-1 sequence. In close parallelism, TRX-1 can 
also translocate into the nucleus under certain conditions [7] without such targeting 
signal in its sequence. The roles of TRX-1 in nucleus and cytoplasm seem to be 
different [7,35] and it has been shown that nuclear TRX-1 modulates, in a redox-
dependent manner, the DNA binding activity of transcription factors [15,36], including 
nuclear receptors [6,19]. Taken together, we may speculate that regulation of activity 
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of transcription factors might be one role of TXL-1 within the nucleus and that TXL-1 
might be an important factor in protecting nervous system against the effects of 
hypoglycemia. 
TXL-1 expression is clearly modulated by glucose deprivation in HEK-293 cells 
since TXL-1 protein levels are reduced after 36 h in this condition (see Fig. 5B). 
Unlike TXL-1, TRX-1 levels do not change after 48 h in a glucose-free medium. This 
result indicates that TXL-1 might be specifically involved in the cellular response to 
glucose deprivation. It is well accepted that glucose deprivation-induced cytotoxicity 
is mediated by the generation of ROS, e.g. hydrogen peroxide, that promotes the 
activation of the c-Jun N-terminal kinase (JNK-1) pathway through the disruption of 
the interaction between TRX-1 and the apoptosis signaling kinase-1 (ASK-1). The 
activation of this pathway leads to the progression of the apoptotic process and cell 
death [29-31]. However, TXL-1 expression is not affected by hydrogen peroxide 
exposure, so the effect of glucose deprivation on TXL-1 expression must be 
mediated through a different pathway where hydrogen peroxide is not involved. 
We have also found that overexpression of TXL-1 over a certain threshold can 
protect HEK-293 cells against glucose deprivation cytotoxicity. Significant 
differences in cell survival appear after 48 h treatment when comparing clones with 
highest TXL-1 levels. Before 36 h, cell survival is comparable in all clones, most 
probably because TXL-1 levels are high enough to maintain the cellular integrity. 
However, after 36 h and onwards only the TXL-1-6 clone showing the highest 
expression level is able to protect cells to some extent from glucose deprivation-
induced cytotoxicity. Again, hydrogen peroxide-induced cytotoxicity is not prevented 
by TXL-1 overexpression supporting our previous idea that TXL-1 must function in a 
pathway where hydrogen peroxide is not involved. 
In summary, we propose TXL-1 to be involved in the cellular response against 
glucose deprivation. However, more experiments are required to elucidate the 
specific mechanism and the molecular targets of TXL-1 in this particular process.  
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Figure Legends 
 
Fig. 1. Reducing activity of human TXL-1. TRX-1 () and purified TXL-1 (, 
10µg; , 20µg) were assayed for their ability to reduce insulin disulfide bonds in the 
presence of NADPH and calf thymus thioredoxin reductase (TrxR-1). Reactions with 
TrxR-1 alone (O) served as controls. A total of 1µg of TrxR-1 was used in each 
reaction. Identical results were obtained from three independent experiments. 
 
Fig. 2. Localization of Txl-1 mRNA in mouse tissues with in situ hybridization. 
High expression of Txl-1 mRNA can be seen in the hippocampus (hc) and the 
hypothalamus (hy). Arrowheads show arcuate nucleus of hypothalamus and arrows 
point to habenular nucleus. Cerebral cortex (co) exhibits moderate signal (A). Strong 
signal is present in the granular cell layer of cerebellar cortex (co) and some nuclei 
of brain stem (bs) (B). Neurons (arrowheads) of trigeminal ganglion show moderate 
expression (C). In ovary prominent signal is seen in different size follicles 
(arrowheads) while interstitial tissue (it) shows low expression (D). Most of the 
seminiferous tubules (arrowheads) of testis exhibit moderate signal (E). The 
epithelium of the tubules (arrowheads) of epididymis shows strong signal (F). Low 
signal is present in the epithelium (arrowheads) in prostate (G). Moderate expression 
is seen throughout the thymus (H). In kidney moderate signal is present in cortex 
(co) and outer medulla (om) while inner medulla (im) and renal pelvis are non-
labelled (I). 
Homogenous expression can be seen liver (J). Low expression is present in adrenal 
cortex (co) and medulla (me) (K). In heart very low signal is in heart muscle (L). In 
skeletal muscle (mu) of tongue low signal is present and the epithelium (arrowheads) 
shows somewhat stronger signal (M). In placenta (pl) strong signal is seen in the 
fetal part (arrowheads) while maternal part and uterus (triangels) shows low 
expression. Clear signal is present in the neuroepithelium (arrow) of neural tube of 
E9 fetus (N). Bar in A represent 210 µm (A, F), 230 µm (B), 100 µm (C, E, G), 180 
µm (D, H, I, L), 35 µm (J), 65 µm (K), 90 µm (M) and 240 µm (N). 
 
Fig. 3. Immunolocalization of Txl-1 in brain tissue. A, Txl-1 immunoreactivity in 
cerebellar cortex. Strong nuclear (arrow) and moderate cytoplasmic staining 
(arrowheads) can be seen in the Purkinje cell (pc). Large number of granular 
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neurons (gc) show strong nuclear and moderate cytoplasmic labeling (arrows) while 
few exhibit only moderate cytoplasmic staining (double arrowheads) (mc, molecular 
layer). B, Txl-1 immunoreactivity in hypothalamic arcute nucleus. Some neurons 
show clear cytoplasmic staining with low nuclear labeling (arrowheads) while other 
neurons exhibit strong nuclear labeling (arrows). C, presaturation control of the 
adjacent section to B, no staining can be seen in the control. Bar in A represents 
30µm for A-C. 
 
Fig. 4. Effect of glucose deprivation on HEK-293 cells and TXL-1 protein levels. 
Left panel, HEK-293 cells were cultured in a glucose-free medium during 48 h. Cell 
survival was calculated using the MTT assay and it is represented as a percentage 
of living cells compared with HEK-293 cells grown in medium with glucose. Right 
panel, HEK-293 cells were cultured in a glucose-containing medium and a glucose-
free medium during 48 h. Cell lysates (25µg) from representative time-points were 
separated by SDS-PAGE and immunoblotted with anti-TXL-1, anti-TRX-1 and anti-β-
actin. 
 
Fig. 5. Effect of hydrogen peroxide on HEK-293 cells and TXL-1 protein levels. 
Right panel, HEK-293 cells were cultured in the presence of 0.5mM H2O2 during 6 h. 
Cell survival was calculated using the Trypan Blue exclusion assay. Left panel, 
crude protein extracts (25µg) from HEK-293 cells treated (0-6 h) with 0.5mM H2O2 
were subjected to western-blot analysis using the anti-TXL-1 and anti-β-actin 
antibodies. 
 
Fig. 6. Overexpression of TXL-1 protects HEK-293 cells against glucose 
deprivation-induced cytotoxicity. Upper panel, cell lysates (25µg) from non 
transfected (n. t.) HEK-293 cells or cells transfected with empty pCDNA-myc or 
pCDNA-myc/TXL-1 (clones 6 and 16) were separated by SDS-PAGE and 
immunoblotted with anti-TXL-1 and anti-β-actin. Extracts from TXL-1-6 and TXL-1-16 
clones show two bands with anti-TXL-1 antibody corresponding to the endogenous 
TXL-1 (lower band) and the myc-TXL-1 (upper band). Lower panel, cell viability MTT 
assay of HEK-293 stably transfected cells (TXL-1-6 and TXL-1-16) compared with 
HEK-293 cells stably transfected with the empty pCDNA-myc vector. Bars indicate 
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mean ± SEM with data expressed as percentage of living cells. Comparisons among 
clones were performed using ANOVA followed by the Student-Newman-Keuls post-
hoc test (N=8, P<0.05). Statistical significant differences are indicated with an 
asterisk. 
 
Supplemental Data Fig. 1. Sequence comparison of Txl-1 proteins from several 
representative eukaryotic species. The alignment was performed using the W-
CLUSTAL program included in the DNAStar package [34]. Identical residues are 
shadowed, the thioredoxin domain is indicated with an arrow and the thioredoxin-
active site is boxed. 
 
Supplemental Data Figure 2. Subcellular localization of human TXL-1. A TXL-1-
GFP construct transfected into HEK-293 cells shows green fluorescence in the 
nucleus and cytosol. pEGFP-N3 vector expressing GFP alone was transfected into 
HEK-293 cells as a control of nuclear and cytoplasmic staining. A SPTRX-2-GFP 
construct was used as a cytoplasmic control in the same HEK-293 cells. All 
micrographs were obtained from a single focal section.  
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